araag2/HINT huggingface dataset:
Clinical trial NCT00573937 (phase 2, status: terminated)
Conditions: neoplasms, pain
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: methadone, morphine
SMILES: CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a telephone

          -  Age: patient must be 18 years or older and less than 70 years of age

          -  Life expectancy of 3 months or greater

          -  No prior use of step-3 opioids (step 2 opioids are allowed)

          -  Provision of informed consent

          -  Score of 26 or greater on Mini-Mental Status Exam (MMSE) (to be done by investigator
             if there is question about mental status)

          -  Nonmalignant pain will be excluded; however, if the patient has both malignant and
             nonmalignant pain, entry into the trial will be determined by the predominant site of
             pain

          -  Moderate to severe cancer related pain that requires the use of step-3 opioids

          -  Normal renal function

          -  There will be no exclusionary criteria based on Karnofsky score

          -  Must live no more than 1 hour away from clinic

          -  Patient must have pain severity of 5-7/10 on a 0-10 pain scale

        Exclusion Criteria:

          -  Nursing home patients

          -  Obvious cognitive dysfunction

          -  Intractable nausea or vomiting

          -  A true allergy or intolerance to opioids

          -  Unstable renal function

          -  Undergoing therapeutic procedures likely to influence pain during the study period

          -  Gastrointestinal pathology or surgery that influences absorption of morphine or
             methadone

          -  Must not have had treatment with radiotherapy, chemotherapy or radionuclides in the
             last 30 days

          -  History of drug seeking behavior

          -  Respiratory compromise

          -  Treatment with bisphosphonates within the last month

          -  Use of MAO inhibitors

          -  Drugs that interfere with CYP34A or CYP2D6

          -  Drugs that interfere with morphine metabolism

          -  Retroviral therapies

          -  Active radiation or antineoplastic therapies

          -  Hepatic dysfunction

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic disease
             (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the study

          -  Study will exclude women who are pregnant and/or nursing

          -  Women who are of child bearing potential must have a negative urine pregnancy test

          -  Patients with a recent substance abuse history will be excluded

          -  Patients with major depression will be excluded
Clinical trial NCT00642707 (phase 2, status: completed)
Conditions: hiv -1 infection, hiv infections
ICD codes: Z21
Drugs: pro 140 (humanized monoclonal antibody to ccr5), placebo comparator
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. Males & females, age ≥ 18 years (or minimum adult age as determined by local
             regulatory authorities)

          2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL

          3. CD4+ lymphocyte cell count ≥ 300 cells/mm3 and no documented count < or = 250
             cells/mm3

          4. Has not taken any antiretroviral therapy (ART) w/in 12 wks of Early Screening Visit

          5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit

          6. Clinically normal or "not clinically significant (NCS)" resting electrocardiogram

          7. Women of reproductive potential must have a negative serum pregnancy test at Late
             Screening Visit & a negative urine pregnancy test w/in 72 hrs prior to first dose of
             study medication, & be non-lactating. Male & female subjects must agree not to
             participate in a conception process from Early Screening Visit through Day 59.

        Exclusion Criteria:

          1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.

          2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant
             during the study.

          3. History of active hepatitis within the previous 24 wks

          4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, including
             PRO 140, experimental or approved.

          5. Any immunization or vaccination (including influenza vaccine) within 30 days prior to
             administration of study drug.
Clinical trial NCT01356160 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: gs-5885, gs-9451, ribavirin tablet, gs-9451 placebo
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 18-70 years of age

          -  Chronic HCV infection

          -  Subjects must have liver biopsy results (≤ 2 years prior to Screening) indicating the
             absence of cirrhosis.

          -  Monoinfection with HCV genotype 1

          -  HCV RNA > 10^4 IU/mL at Screening

          -  HCV treatment naïve

          -  Candidate for PEG/RBV therapy

          -  Body mass index (BMI) 18-36 kg/m2, inclusive

          -  Agree to use two forms of highly effective contraception methods for the duration of
             the study and for 7 months after the last dose of study medication. Females of
             childbearing potential must have negative pregnancy test at Screening and Baseline.

        Exclusion Criteria:

          -  Pregnant female or male with pregnant female partner

          -  Exceed defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia,
             thyroid stimulating hormone (TSH)

          -  Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled
             diabetes mellitus, significant psychiatric illness, severe chronic obstructive
             pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or
             other malignancy (with exception of certain resolved skin cancers), hemoglobinopathy,
             retinal disease, or are immunosuppressed.

          -  Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin),
             or ongoing alcohol abuse are excluded. Patients on stable methadone or buprenorphine
             maintenance treatment for at least 6 months prior to Screening may be included into
             the study.
Clinical trial NCT00722046 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females of non childbearing potential, age > or = 50

          -  Diagnosis of probable Alzheimer's disease, consistent with criterial from both:

               -  National Institute of Neurological and Communicable Disease and Stroke and
                  Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)

               -  Diagnostic and Statistical Manual of Mental Disorders (DSM IV)

          -  Mini-mental status exam score of 16-26 inclusive

          -  Rosen-Modified Hachinski Ischemia Score of < or = 4

        Exclusion Criteria:

          -  Diagnosis or history of other demential or neurodegenerative disorders

          -  Diagnosis or history of clinically significant cerebrovascular disease

          -  Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro
             hemorrhage, multiple white matter lacunes, extensive white matter abnormalities

          -  History of autoimmune disorders

          -  History of allergic or anaphylactic reactions
Clinical trial NCT00293826 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: amg 108, amg 108, amg 108, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with active rheumatoid arthritis as diagnosed by meeting ACR classification
             criteria for at least 6 months.

          -  Must be taking MTX consecutively for >/= 12 weeks and at a stable dose of methotrexate
             at 15-25 mg weekly for at least 4 weeks prior to screening

        Exclusion Criteria:

          -  Receipt of commercial or experimental biologic therapies for the treatment of
             inflammatory disease

          -  Presence of serious infection

          -  Class IV rheumatoid arthritis

          -  Prior or current history of tuberculosis infection or exposure

          -  Any other DMARDs other than methotrexate within 6 weeks of screening

          -  Pregnant or nursing

          -  Receipt of live vaccines within 3 months

          -  Felty's syndrome
Clinical trial NCT01330238 (phase 2, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: zoledronic acid vs. placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  age over 18 years old

          -  low back pain for more than 3 months

          -  Modic type I or II change in lumbar magnetic resonance imaging

          -  Intensity of low back pain at least 6 on 10-cm VAS or Oswestry disability score at
             least 30%

        Exclusion Criteria:

          -  premenopausal female patients with possibility of pregnancy

          -  patients with calculated creatinine clearance of less than 40 ml/min

          -  patients with hypocalcemia

          -  patients with known hypersensitivity to zoledronic acid or other bisphosphonates or
             ingredients of the infusional product

          -  patients with red flags symptoms

          -  patients with nerve root impingement

          -  patients with willingness for early retirement
Clinical trial NCT00628251 (phase 2, status: completed)
Conditions: ovarian neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd2281, liposomal doxorubicin, azd2281
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced ovarian cancer with positive BRCA1 or BRCA2 status

          -  Progressive or recurrent disease after platinum-based chemotherapy

          -  Measurable disease by RECIST

        Exclusion Criteria:

          -  Previous anthracycline treatment

          -  Brain metastases

          -  Less than 28 days since last treatment used to treat the disease

          -  Considered a poor medical risk due to a serious uncontrolled disorder
Clinical trial NCT01147458 (phase 2, status: terminated)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: pf-04191834, pf-04191834 placebo, naproxen placebo, pf-04191834 placebo, pf-04191834, naproxen placebo, pf-04191834, naproxen, pf-04191834 placebo, naproxen, pf-04191834 placebo, pf-04191834
SMILES: CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1, CN1N=CC=C1C1=CC=C(SC2=CC=CC(=C2)C2(CCOCC2)C(N)=O)C=C1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a diagnosis of osteoarthritis based on the American College of
             Rheumatology criteria confirmed by an X-ray

          -  Subjects must be willing and able to stop all current pain therapy for the duration of
             the study

          -  Subjects must be willing and able to complete a daily diary

        Exclusion Criteria:

          -  BMI of >39 kg/m2

          -  Known allergy or hypersensitivity to naproxen

          -  Any condition or medical history that might interfere with the subject's ability to
             complete the study visits and assessments
Clinical trial NCT01369095 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: duloxetine, escitalopram, bms-820836 placebo, bms-820836, bms-820836, bms-820836, bms-820836
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women of age 18-65 years (Argentina minimum age will be 24 years of age)

          -  Patients must be able to understand the nature of the study, agree to comply with the
             prescribed dosage regimens, report for regularly scheduled office visits, and
             communicate to study personnel about adverse events and concomitant medication use.

          -  Patients with a diagnosis of Major Depressive Disorder, currently experiencing a Major
             Depressive Episode, as defined by Diagnostic and Statistical Manual of Mental
             Disorders- Fourth Edition (Text Revision)[DSM IV TR] criteria. The current depressive
             episode must be > 8 weeks in duration and < 3 years duration.

          -  In the current Major depressive disorder (MDD) episode, patients should report a
             history of inadequate response to 1-3 adequate trials of antidepressant treatment.

          -  Patients must have a 17-item Hamilton Depression Rating Scale (HAM-D17) total score ≥
             18 at Screening and Baseline.

        Exclusion Criteria:

          -  Patients who report an inadequate response (less than 50% reduction in depressive
             symptom severity) to more than three adequate trials of antidepressant treatments
             during the current depressive episode.

          -  Patients who have failed Duloxetine and Escitalopram at an adequate dose and for an
             adequate duration in their current episode.
Clinical trial NCT00448721 (phase 2, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: perifosine
SMILES: CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be required to have clear cell renal cell carcinoma with less than 50%
             of any other histology (papillary or chromophobe or oncocytic). There must be
             histologic confirmation by the treating center of either the primary or a metastatic
             lesion

          -  Patients must have experienced disease progression by RECIST criteria while on
             sorafenib or sunitinib

          -  Patients must be off of sorafenib or sunitinib for >= 2 weeks prior to initiation of
             perifosine and <= 3 months prior to enrollment

          -  Patients may have had sorafenib or sunitinib in the adjuvant setting as long as they
             have experienced disease recurrence while on therapy

          -  Patients must have measurable disease that is not curable by standard radiation
             therapy or surgery

          -  Age >= 18 years

          -  ECOG performance status 0 or 1

          -  - Patients must have the ability to understand and willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  History or clinical evidence of CNS disease, including primary brain tumor, seizures
             not controlled with standard medical therapy, any brain metastasis, or history of
             stroke

          -  Other than sorafenib or sunitinib, patients may have only had prior immunotherapy for
             stage IV disease

          -  Patients may have had prior sorafenib OR sunitinib and cannot have been treated with
             both TKIs

          -  Patients who have stopped sorafenib or sunitinib due to toxicity but have only
             progressed off therapy will not be allowed

          -  Patients may have had prior anti-angiogenic such as bevacizumab only if given in
             combination with either sorafenib or sunitinib

          -  Prior Thalidomide or IFNα are allowed for adjuvant therapy or stage IV disease

          -  Patients may not have had prior mTOR inhibitors (CCI-779, RAD001)
Clinical trial NCT00695019 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: interferon-alpha lozenges, placebo lozenges
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  HCV genotype 1b

          -  Will be completing pegylated IFN-alpha and ribavirin therapy within 4 weeks

          -  Serum HCV RNA negative within 4 weeks of study entry

        Exclusion Criteria:

          -  Child-Pugh score of B or C

          -  Decompensated liver function

          -  History of malignancy within past 5 years

          -  Other causes of liver disease besides HCV infection

          -  Uncontrolled diabetes or hypertension

          -  Unwilling to use two forms of birth control during study treatment
Clinical trial NCT00613379 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: pro 140, pro 140, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males & females, age ≥ 18 years (or minimum adult age as determined by local
             regulatory authorities)

          2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL

          3. CD4+ T-lymphocyte cell count ≥ 300 cells/mm3 and no documented count < or = 250
             cells/mm3

          4. Has not taken any anti-retroviral therapy (ART) w/in 12 wks of Early Screening Visit

          5. Exclusive CCR5-tropic virus as determined by Trofile™ Assay at Early Screening Visit

          6. Clinically normal or "not clinically significant (NCS)" resting electrocardiogram

          7. Women of reproductive potential must have a negative serum pregnancy test at Late
             Screening Visit & a negative urine pregnancy test w/in 72 hrs prior to first dose of
             study medication, & be non-lactating. Male & female subjects must agree not to
             participate in a conception process from Early Screening Visit through Day 59.

        Exclusion Criteria:

          1. CXCR4 tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ Assay.

          2. Females who are pregnant, lactating or breastfeeding, or who plan to become pregnant
             during the study.

          3. History of active hepatitis within the previous 24 wks

          4. Prior use of any entry, attachment, CCR5 co-receptor or fusion inhibitor, experimental
             or approved.
Clinical trial NCT00239343 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  histologically confirmed oestrogen receptor negative primary breast cancer, tumour
             stage T2-3, N0-2, M0. Eligible for surgery, WHO performance score 0-1.

        Exclusion Criteria:

          -  any prior anticancer therapy including gefitinib (Iressa®), epirubicin
             (Farmorubicin™), or cyclophosphamide, distant metastases or bilateral breast cancer,
             any evidence of clinically active interstitial lung disease , other co-existing
             malignancies or malignancies diagnosed within the last 5 years with the exception of
             basal cell carcinoma or cervical cancer in situ, pregnancy or breastfeeding
Clinical trial NCT01375777 (phase 2, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: ezetimibe
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 75 years of age

          -  Low density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and < 190 mg/dL

          -  Framingham risk score of 10% or less

          -  Fasting triglycerides < 400 mg/dL

        Exclusion Criteria:

          -  History of coronary heart disease

          -  New York Heart Association (NYHA) II - IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension